<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Synovitis &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/synovitis/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Tue, 02 Jun 2026 12:26:33 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Synovitis &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study of intra-articular liraglutide (4P004) for patients with knee synovitis and osteoarthritis</title>
		<link>https://clinicaltrials.eu/trial/study-of-intra-articular-liraglutide-4p004-for-patients-with-knee-synovitis-and-osteoarthritis/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 15:06:39 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-of-intra-articular-liraglutide-4p004-for-patients-with-knee-synovitis-and-osteoarthritis/</guid>

					<description><![CDATA[This clinical trial investigates a new treatment for patients with knee synovitis and osteoarthritis, conditions that cause pain and inflammation in the knee joint. The study will test a medication called 4P-004, which contains the active substance liraglutide, given through intra-articular injection directly into the knee joint. The purpose of this research is to determine [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial investigates a new treatment for patients with <b>knee synovitis</b> and <b>osteoarthritis</b>, conditions that cause pain and inflammation in the knee joint. The study will test a medication called <b>4P-004</b>, which contains the active substance <b>liraglutide</b>, given through <b>intra-articular injection</b> directly into the knee joint.</p>
<p>The purpose of this research is to determine how well 4P-004 works in reducing knee pain and whether it is safe to use. During the study, participants will receive either 4P-004 or <b>placebo</b> injections. The treatment period lasts 12 weeks, during which participants will have their knee pain and overall condition regularly evaluated.</p>
<p>The medication will be administered as an injection solution, with a maximum daily dose of 2 milligrams. Throughout the study, participants will undergo various assessments to monitor their response to treatment, including evaluations of pain levels during daily activities and overall knee function. The study includes regular check-ups to monitor the participants&#8217; health and safety.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Study on the Safety and Effects of AMB-05X Injections for Patients with Tenosynovial Giant Cell Tumor</title>
		<link>https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-amb-05x-injections-for-patients-with-tenosynovial-giant-cell-tumor/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 14:26:38 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-amb-05x-injections-for-patients-with-tenosynovial-giant-cell-tumor/</guid>

					<description><![CDATA[This clinical trial is focused on studying a condition known as Tenosynovial Giant Cell Tumor (TGCT). TGCT is a type of tumor that affects the joints, causing pain and stiffness. The treatment being tested in this study is called AMB-05X, which is administered as a solution for injection directly into the joint. The purpose of [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial is focused on studying a condition known as <i>Tenosynovial Giant Cell Tumor</i> (TGCT). TGCT is a type of tumor that affects the joints, causing pain and stiffness. The treatment being tested in this study is called <i>AMB-05X</i>, which is administered as a solution for injection directly into the joint. The purpose of the study is to evaluate the safety and effectiveness of AMB-05X in treating TGCT.</p>
<p>The study is divided into two parts. In the first part, participants will receive treatment with AMB-05X for 24 weeks. During this time, researchers will monitor how well the treatment works and any side effects that may occur. After the initial treatment period, participants may continue into the second part of the study, which involves extended treatment and observation. This part aims to gather more information on the long-term effects of the treatment.</p>
<p>Throughout the study, participants will undergo various assessments, including imaging tests like <i>MRI</i> scans, to measure the size of the tumor and evaluate the response to the treatment. The study will also track changes in joint movement, pain levels, and overall physical function. By participating in this study, researchers hope to gain valuable insights into the potential benefits of AMB-05X for individuals with TGCT.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
